The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer
Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we ev...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2013-06, Vol.30 (2), p.551-551, Article 551 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 551 |
|---|---|
| container_issue | 2 |
| container_start_page | 551 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 30 |
| creator | Ustaalioglu, Bala Basak Oven Bilici, Ahmet Ercan, Serif Seker, Mesut Orcun, Asuman Gumus, Mahmut |
| description | Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we evaluated the clinical importance of the change in serum M30 and M65 values after chemotherapy in patients with NSCLC. Serum M30 and M65 values were measured before and 48 h after chemotherapy in thirty-two patients with advanced NSCLC. The importance of the change in the levels of these markers after chemotherapy was analyzed by univariate analysis. The median serum M65 and M30 values increased significantly after chemotherapy (
p
|
| doi_str_mv | 10.1007/s12032-013-0551-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1321796480</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1321796480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-f0cb4473f5accdb86796ab3da219638c81bbad332c91c2967f01db82326d916b3</originalsourceid><addsrcrecordid>eNp1kctq3TAQhkVpaW59gG6KoJtu1GgkSz5elpBeICGbFLITY1n2cbAlV5IT8g596MqctJRCVxqYbz7N8BPyFvhH4Lw-TyC4FIyDZFwpYPoFOQalGgYS7l6WWqq6dDQ_Iicp3XMuQInmNTkSUknNORyTn7d7R5cYBh9SHi0d5yXEjN46Gnpq9-iH0Q80ubjO9Fpyir6j11rRB5xWlyj22cXCuTnkvYu4PNHR0wXz6HxO9HHMe4rdwybsWMo4OOqDZ2nGaWLWTROd1uK3GxDPyKsep-TePL-n5Pvny9uLr-zq5su3i09XzMpaZNZz21ZVLXuF1nbtTteNxlZ2KKDRcmd30LbYSSlsA1Y0uu45FExIobsGdCtPyYeDtxz-o1yRzTymbRn0LqzJgBRQnNWOF_T9P-h9WKMv2xVK6aqSldCFggNlY0gput4scZwxPhngZovKHKIyJSqzRWW2mXfP5rWdXfdn4nc2BRAHIJWWH1z86-v_Wn8BseifIA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356443426</pqid></control><display><type>article</type><title>The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Ustaalioglu, Bala Basak Oven ; Bilici, Ahmet ; Ercan, Serif ; Seker, Mesut ; Orcun, Asuman ; Gumus, Mahmut</creator><creatorcontrib>Ustaalioglu, Bala Basak Oven ; Bilici, Ahmet ; Ercan, Serif ; Seker, Mesut ; Orcun, Asuman ; Gumus, Mahmut</creatorcontrib><description>Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we evaluated the clinical importance of the change in serum M30 and M65 values after chemotherapy in patients with NSCLC. Serum M30 and M65 values were measured before and 48 h after chemotherapy in thirty-two patients with advanced NSCLC. The importance of the change in the levels of these markers after chemotherapy was analyzed by univariate analysis. The median serum M65 and M30 values increased significantly after chemotherapy (
p
< 0.001). The median M30 value after chemotherapy was an important prognostic factor for both overall survival (OS) (
p
= 0.002) and progression-free survival (PFS) (
p
= 0.002). Stage and histopathological type were significant both for PFS and OS. Multivariate analysis showed that the median M30 value after chemotherapy was the only independent prognostic factor for PFS (
p
= 0.04, HR 5.4) and OS (
p
= 0.02, HR 11.49). Our results indicated that both serum M30 and M65 values increased after chemotherapy in patients with advanced NSCLC, and an elevated serum M30 value was an independent prognostic factor for both PFS and OS.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-013-0551-6</identifier><identifier>PMID: 23536001</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Biomarkers, Tumor - biosynthesis ; Biomarkers, Tumor - blood ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Disease Progression ; Disease-Free Survival ; Female ; Follow-Up Studies ; Hematology ; Humans ; Internal Medicine ; Keratin-18 - biosynthesis ; Keratin-18 - blood ; Lung cancer ; Lung Neoplasms - blood ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Paper ; Pathology ; Peptide Fragments - biosynthesis ; Peptide Fragments - blood ; Prognosis ; Survival Rate - trends ; Treatment Outcome</subject><ispartof>Medical oncology (Northwood, London, England), 2013-06, Vol.30 (2), p.551-551, Article 551</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-f0cb4473f5accdb86796ab3da219638c81bbad332c91c2967f01db82326d916b3</citedby><cites>FETCH-LOGICAL-c372t-f0cb4473f5accdb86796ab3da219638c81bbad332c91c2967f01db82326d916b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-013-0551-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-013-0551-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23536001$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ustaalioglu, Bala Basak Oven</creatorcontrib><creatorcontrib>Bilici, Ahmet</creatorcontrib><creatorcontrib>Ercan, Serif</creatorcontrib><creatorcontrib>Seker, Mesut</creatorcontrib><creatorcontrib>Orcun, Asuman</creatorcontrib><creatorcontrib>Gumus, Mahmut</creatorcontrib><title>The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we evaluated the clinical importance of the change in serum M30 and M65 values after chemotherapy in patients with NSCLC. Serum M30 and M65 values were measured before and 48 h after chemotherapy in thirty-two patients with advanced NSCLC. The importance of the change in the levels of these markers after chemotherapy was analyzed by univariate analysis. The median serum M65 and M30 values increased significantly after chemotherapy (
p
< 0.001). The median M30 value after chemotherapy was an important prognostic factor for both overall survival (OS) (
p
= 0.002) and progression-free survival (PFS) (
p
= 0.002). Stage and histopathological type were significant both for PFS and OS. Multivariate analysis showed that the median M30 value after chemotherapy was the only independent prognostic factor for PFS (
p
= 0.04, HR 5.4) and OS (
p
= 0.02, HR 11.49). Our results indicated that both serum M30 and M65 values increased after chemotherapy in patients with advanced NSCLC, and an elevated serum M30 value was an independent prognostic factor for both PFS and OS.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Keratin-18 - biosynthesis</subject><subject>Keratin-18 - blood</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Peptide Fragments - biosynthesis</subject><subject>Peptide Fragments - blood</subject><subject>Prognosis</subject><subject>Survival Rate - trends</subject><subject>Treatment Outcome</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kctq3TAQhkVpaW59gG6KoJtu1GgkSz5elpBeICGbFLITY1n2cbAlV5IT8g596MqctJRCVxqYbz7N8BPyFvhH4Lw-TyC4FIyDZFwpYPoFOQalGgYS7l6WWqq6dDQ_Iicp3XMuQInmNTkSUknNORyTn7d7R5cYBh9SHi0d5yXEjN46Gnpq9-iH0Q80ubjO9Fpyir6j11rRB5xWlyj22cXCuTnkvYu4PNHR0wXz6HxO9HHMe4rdwybsWMo4OOqDZ2nGaWLWTROd1uK3GxDPyKsep-TePL-n5Pvny9uLr-zq5su3i09XzMpaZNZz21ZVLXuF1nbtTteNxlZ2KKDRcmd30LbYSSlsA1Y0uu45FExIobsGdCtPyYeDtxz-o1yRzTymbRn0LqzJgBRQnNWOF_T9P-h9WKMv2xVK6aqSldCFggNlY0gput4scZwxPhngZovKHKIyJSqzRWW2mXfP5rWdXfdn4nc2BRAHIJWWH1z86-v_Wn8BseifIA</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Ustaalioglu, Bala Basak Oven</creator><creator>Bilici, Ahmet</creator><creator>Ercan, Serif</creator><creator>Seker, Mesut</creator><creator>Orcun, Asuman</creator><creator>Gumus, Mahmut</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer</title><author>Ustaalioglu, Bala Basak Oven ; Bilici, Ahmet ; Ercan, Serif ; Seker, Mesut ; Orcun, Asuman ; Gumus, Mahmut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-f0cb4473f5accdb86796ab3da219638c81bbad332c91c2967f01db82326d916b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Keratin-18 - biosynthesis</topic><topic>Keratin-18 - blood</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Peptide Fragments - biosynthesis</topic><topic>Peptide Fragments - blood</topic><topic>Prognosis</topic><topic>Survival Rate - trends</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ustaalioglu, Bala Basak Oven</creatorcontrib><creatorcontrib>Bilici, Ahmet</creatorcontrib><creatorcontrib>Ercan, Serif</creatorcontrib><creatorcontrib>Seker, Mesut</creatorcontrib><creatorcontrib>Orcun, Asuman</creatorcontrib><creatorcontrib>Gumus, Mahmut</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ustaalioglu, Bala Basak Oven</au><au>Bilici, Ahmet</au><au>Ercan, Serif</au><au>Seker, Mesut</au><au>Orcun, Asuman</au><au>Gumus, Mahmut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>30</volume><issue>2</issue><spage>551</spage><epage>551</epage><pages>551-551</pages><artnum>551</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Although oncological treatments are improving, the prognosis of non-small-cell lung cancer (NSCLC) patients has not. Several biomarkers related to prognosis have been evaluated, and M30 and M65 have been reported to be higher in patients with NSCLC than in healthy people. In the current study, we evaluated the clinical importance of the change in serum M30 and M65 values after chemotherapy in patients with NSCLC. Serum M30 and M65 values were measured before and 48 h after chemotherapy in thirty-two patients with advanced NSCLC. The importance of the change in the levels of these markers after chemotherapy was analyzed by univariate analysis. The median serum M65 and M30 values increased significantly after chemotherapy (
p
< 0.001). The median M30 value after chemotherapy was an important prognostic factor for both overall survival (OS) (
p
= 0.002) and progression-free survival (PFS) (
p
= 0.002). Stage and histopathological type were significant both for PFS and OS. Multivariate analysis showed that the median M30 value after chemotherapy was the only independent prognostic factor for PFS (
p
= 0.04, HR 5.4) and OS (
p
= 0.02, HR 11.49). Our results indicated that both serum M30 and M65 values increased after chemotherapy in patients with advanced NSCLC, and an elevated serum M30 value was an independent prognostic factor for both PFS and OS.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23536001</pmid><doi>10.1007/s12032-013-0551-6</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2013-06, Vol.30 (2), p.551-551, Article 551 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1321796480 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - blood Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Disease Progression Disease-Free Survival Female Follow-Up Studies Hematology Humans Internal Medicine Keratin-18 - biosynthesis Keratin-18 - blood Lung cancer Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Oncology Original Paper Pathology Peptide Fragments - biosynthesis Peptide Fragments - blood Prognosis Survival Rate - trends Treatment Outcome |
| title | The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A04%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20prognostic%20importance%20of%20changing%20serum%20M30%20and%20M65%20values%20after%20chemotherapy%20in%20patients%20with%20advanced-stage%20non-small-cell%20lung%20cancer&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Ustaalioglu,%20Bala%20Basak%20Oven&rft.date=2013-06-01&rft.volume=30&rft.issue=2&rft.spage=551&rft.epage=551&rft.pages=551-551&rft.artnum=551&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-013-0551-6&rft_dat=%3Cproquest_cross%3E1321796480%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356443426&rft_id=info:pmid/23536001&rfr_iscdi=true |